The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline

JAMA Neurology

Volumn 71, Issue 8, 2014, Pages 961-970

  Donohue, Michael C ^a,b   Sperling, Reisa A ^c   Salmon, David P ^b   Rentz, Dorene M ^c   Raman, Rema ^a,b   Thomas, Ronald G ^b   Weiner, Michael ^d,e   Aisen, Paul S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; PLACEBO; SOLANEZUMAB; MONOCLONAL ANTIBODY;

AGED; ALLELE; ALZHEIMER DISEASE; ALZHEIMER DISEASE COOPERATIVE STUDY PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE SCORE; ARTICLE; AUSTRALIA; CLINICAL DEMENTIA RATING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; CLINICAL TRIAL (TOPIC); COGNITION DISORDERS; DISEASE COURSE; EARLY DIAGNOSIS; FEASIBILITY STUDY; GENETICS; HETEROZYGOTE; META ANALYSIS; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRODROMAL SYMPTOM; PROSPECTIVE STUDY; STANDARDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; APOLIPOPROTEIN E4; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; EXECUTIVE FUNCTION; FEASIBILITY STUDIES; FEMALE; HETEROZYGOTE; HUMANS; MALE; MEMORY, EPISODIC; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PRODROMAL SYMPTOMS; PROSPECTIVE STUDIES;

EID: 84905969638     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.803     Document Type: Article

References (51)

1. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292.
2. Bateman RJ, Xiong C, Benzinger TL, et al Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804.
3. Villemagne VL, Burnham S, Bourgeat P, et al Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-367.
4. Donohue MC, Jacqmin-Gadda H, Le Goff M, et al Alzheimer's Disease Neuroimaging Initiative. Estimating long-term multivariate progression from short-term data [published online March 24, 2014]. Alzheimers Dement. doi:10.1016/j.jalz.2013.10.003.
5. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-746. (Pubitemid 47058377)
6. Aisen PS, Andrieu S, Sampaio C, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011;76(3):280-286.
7. AlbertMS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279.
8. Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(111):111cm33.
9. Jack CR Jr, Barkhof F, Bernstein MA, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement. 2011;7(4):474-485.e4.
10. Reiman EM; Alzheimer's Disease Biomarkers Working Group for the Alliance for Aging Research. Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments. Neurobiol Aging. 2011;32(suppl 1):S44-S47.
11. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363-372.
12. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69(2):198-207.
13. Cummings JL. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement. 2011;7(3):e13-e44.
14. Fox NC, Black RS, Gilman S, et al; AN1792(QS-21)-201 Study. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64(9):1563-1572. (Pubitemid 40617692)
15. Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol. 2008;64(5):492-498.
16. Salmon DP, Ferris SH, Thomas RG, et al. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology. 2013;27(4):391-401.
17. US Dept of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research. Guidance for industry: Alzheimer's disease: developing drugs for the treatment of early stage disease (draft guidance). http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf. Published February 2013. Accessed April 28, 2014.
18. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: Stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):28fs13.
19. EliasMF, Beiser A, Wolf PA, Au R, White RF, D'Agostino RB. The preclinical phase of Alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol. 2000;57(6):808-813. (Pubitemid 30397182)
20. Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc. 2008;14(2):266-278. (Pubitemid 351280005)
21. Derby CA, Burns LC, Wang C, et al. Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. Neurology. 2013;80(14):1307-1314.
22. Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010;74(10):807-815.
23. Landau SM, Mintun MA, Joshi AD, et al Alzheimer's Disease Neuroimaging Initiative. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72 (4):578-586.
24. Snitz BE, Weissfeld LA, Lopez OL, et al. Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia. Neurology. 2013;80(15):1378-1384.
25. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66(12):1469-1475.
26. Lim YY, Ellis KA, Pietrzak RH, et al AIBL Research Group. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology. 2012;79(16):1645-1652.
27. Knopman DS, Jack CR Jr, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012;78 (20):1576-1582.
28. Doraiswamy PM, Sperling RA, Coleman RE, et al; AV45-A11 Study Group. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79 (16):1636-1644.
29. Kawas CH, Greenia DE, Bullain SS, et al. Amyloid imaging and cognitive decline in nondemented oldest-old: the 90+ Study. Alzheimers Dement. 2013;9(2):199-203.
30. Ferris SH, Aisen PS, Cummings J, et al Alzheimer's Disease Cooperative Study Group. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord. 2006;20 (4)(suppl 3):S109-S123. (Pubitemid 44900695)
31. Wechsler D. WMS-R:Wechsler Memory Scale-Revised: Manual. San Antonio, TX: Psychological Corporation; 1987.
32. Wechsler D. Wechsler Adult Intelligence Scale-Revised. San Antonio, TX: Psychological Corporation; 1981.
33. FolsteinMF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
34. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(pt 5):871-882. (Pubitemid 29219261)
35. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201-209.
36. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S13-S21.
37. Ellis KA, Bush AI, Darby D, et al AIBL Research Group. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr. 2009;21(4):672-687.
38. Delis DC, Kramer JH, Kaplan E, Ober BA. The California Verbal Learning Test. San Antonio, TX: Psychological Corporation; 1987.
39. Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol. 1999;12(4):168-179. (Pubitemid 30072300)
40. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48(8):314-318. (Pubitemid 17138128)
41. Akaike H. Information theory as an extension of the maximum likelihood principle. In: Petrov BN, Csaki F, eds. Second International Symposium on Information Theory. Budapest, Hungary: Akadémiai Kiadó; 1973:267-281.
42. Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. Biom J. 2008;50(3):346-363. doi:10.1002/bimj.200810425.
43. Wilding GE, Chandrasekhar R, Hutson AD. A new linear model-based approach for inferences about the mean area under the curve. Stat Med. 2012;31(28):3563-3578. doi:10.1002/sim.5387.
44. Lu K, Luo X, Chen PY. Sample size estimation for repeated measures analysis in randomized clinical trials with missing data. Int J Biostat. 2008;4(1):9.
45. Donohue MC, Gamst AC, Edland SD. longpower: sample size calculation for longitudinal data. http://www.cran.r-project.org/web/packages/longpower/index. html. Published September 21, 2013. Accessed May 1, 2014.
46. The Comprehensive R Archive Network. http://www.cran.r-project.org/. Accessed May 1, 2014.
47. Pinheiro J, Bates D, DebRoy S, Sarkar D. nlme: linear and nonlinear mixed effects models. http://www.cran.r-project.org/web/packages/nlme/index.html. Published March 31, 2014. Accessed May 1, 2014.
48. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York, NY: Springer; 2009.
49. Rizopoulos D. ltm: an R package for latent variable modeling and item response analyses. J Stat Softw. 2006;17(5):1-25. http://www.jstatsoft.org/v17/ i05/. Accessed May 1, 2014.
50. Nelder JA, Mead R. A simplex method for functionminimization. Comput J. 1965;7(4):308-313. doi:10.1093/comjnl/7.4.308.
51. Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med. 2013;368(13):1169-1171.